Life Extension Magazine®

Man sleeping with help of melatonin that supports brain health and aging

Melatonin: The Brain Hormone

Leading researchers have discovered how melatonin guards against brain degeneration brought on by aging and environmental factors. New studies uncover melatonin’s ability to protect against common age-related neurological disorders including Alzheimer’s and Parkinson’s.

Scientifically reviewed by: Dr. Gary Gonzalez, MD, in August 2023. Written by: Stephen Fredericks.

Melatonin: The Brain Hormone

Melatonin was introduced to the United States in 1992 as a “sleep hormone.

While some find melatonin helps restore restful sleep, scientists are finding far more consistent applications for melatonin in the area of brain protection.

New discoveries are validating melatonin’s ability to guard the brain from oxidative stress and the neurodegeneration that occurs as a result of aging and environmental factors.1 With this research, melatonin deserves the title of “brain hormone.”

Scientists are increasingly finding that the age-related decline in melatonin levels may be one factor for the age-related increase in neurodegenerative diseases.2-4 In fact, some symptoms of melatonin deficiency are seen in patients with Alzheimer’s, such as disruption of day/night patterns, mood changes, and delirium.5

Fortunately, supplementing with melatonin in middle age and beyond has been shown to protect against Alzheimer’s as well as reduce the risk of Parkinson’s disease, shrink the size of the infarct area involved in a stroke, and minimize the brain swelling and dysfunction following a head injury. 2,6-13

As if this were not enough, research is also finding that in lab studies melatonin can play a role in longevity by increasing the “longevity protein” SIRT1.14,15 Clearly, melatonin’s beneficial properties extend far beyond sleep.

Melatonin’s Role in Neurodegenerative Diseases

Melatonin’s Role in Neurodegenerative Diseases  

Some scientists think the increase in neurodegenerative diseases as we age may be directly related to the age-related decline in melatonin levels.2-4 Fortunately, oral melatonin supplements are available, which may combat this decline by increasing blood and brain levels of melatonin.6,7

Supplementation with low-cost melatonin thus offers an opportunity to restore the brain’s natural antioxidant protection and potentially prevent age-related changes to the brain.2,4,6,16,17 In fact, melatonin’s effects are so powerful that it’s been designated a drug by the European Medicines Agency (EMA).17

With the onset of menopause, animals (like humans) experience a marked increase in oxidative damage, leading to brain cell dysfunction.18 Studies show that in such animals, melatonin supplementation reverses those harmful effects in a similar manner to hormone replacement—but without the associated risks.18

Melatonin Deficiency Linked to Alzheimer’s Disease

Melatonin deficiency and Alzheimer’s disease are closely linked; profound reductions in melatonin levels have been found in Alzheimer’s disease patients. Melatonin, which is maintained at high levels in the brain and spinal fluid throughout youth and middle age, begins to decline sharply with advancing age—in a fashion that closely parallels the rise of Alzheimer’s incidence.2,19,20

One impressive study found that melatonin levels in the spinal fluid of adults older than 80 were just half those of younger, healthy individuals. 21 But older adults who had Alzheimer’s had dramatically lower levels yet—roughly one-fifth of those in healthy young people.

This connection is often overlooked, but vitally important—especially because some of the symptoms that arise as a result of melatonin deficiency are detected long before other more obvious cognitive Alzheimer’s symptoms present themselves.22 This makes melatonin deficiency one of the earliest indicators of Alzheimer’s disease.

Most notably, these include symptoms such as insomnia and sundowning. Sundowning is a “circadian” (daily rhythm) disturbance in which agitation and activity increase, rather than slow down, as the day wanes.23,24 Sleep disorders (such as insomnia, restlessness, and poor sleep quality) generally increase with age and are a sign of declining melatonin production. Such disorders occur in about 45% of those with Alzheimer’s.

Fortunately, clinical research has demonstrated the value of melatonin supplementation in reversing these and other changes associated with Alzheimer’s, particularly when implemented early in the course of the disease.24,25

Melatonin Fights Brain Changes in Alzheimer’s Disease

In animals given the drug haloperidol (Haldol®), which impairs melatonin synthesis, memory deficits and brain protein changes resembling Alzheimer’s disease arise.26,27 However, when the animals are then supplemented with melatonin, the changes disappear, indicating a critical role for melatonin in protecting neurons.

In addition, melatonin has been found to help combat Alzheimer’s disease by reducing the damage caused by two harmful proteins: amyloid beta proteins and tau proteins.6,20,26,28,29 High levels of these two proteins contribute to the death of brain cells and have been linked to Alzheimer’s disease.

Melatonin also helps fight Alzheimer’s disease by guarding against the harmful effects of aluminum, which is known to produce Alzheimer’s-like oxidative changes in brain cells.28

Together, these biochemical effects help to explain why melatonin supplementation has been found to reduce learning and memory deficits in animal models of Alzheimer’s disease.7,30

Why It’s Important to Start Melatonin Early

Researchers agree that it’s best to start taking melatonin before symptoms arise and before physical changes in brain cells have occurred.

One particular animal study demonstrated just how dramatic melatonin’s preventive properties really are. For the study, scientists used mice that had human genes predisposed to Alzheimer’s disease (these are called transgenic mice).7

By late-middle age, the unsupplemented mice proceeded to develop the behavioral and cognitive deficits typical of the disease. In fact, even before signs of disease were visible, the animals’ brains already manifested the typical increased oxidation and decreased intracellular antioxidant defenses seen in Alzheimer’s.7 Soon their brain cells began to die off.

However, mice that were supplemented with melatonin before any disease was evident showed none of those pathological changes—and they performed normally on cognitive and behavioral tests.

This shows just how powerfully melatonin works as a preventive agent. Unfortunately, it’s been difficult to prove these preventive benefits in people because human trials of interventions for Alzheimer’s tend to start only after the disease has become apparent—and well after the window of opportunity for intervention has closed. Nonetheless, very encouraging findings come from studies showing that Alzheimer’s patients taking melatonin experience improved sleep patterns, less sundowning, and slower progression of cognitive impairment.23,24

Still more evidence that it’s best to start melatonin supplements as early as possible comes from several recent studies of mild cognitive impairment, a condition defined as impairment that precedes actual dementia.31 About 12% of people with mild cognitive impairment proceed to develop dementia each year. In a series of studies, researchers have now shown that people taking between 3 and 24 mg of a fast-acting formulation of melatonin daily for 15 to 60 months performed significantly better on a host of cognitive assessment scales and tests of memory.23,31,32

What You Need to Know
Melatonin: The Brain Hormone

Melatonin: The Brain Hormone

  • Melatonin, a hormone produced in the pineal gland of the brain, is well known as a sleep aid; it is registered as a drug for that purpose in Europe.
  • Melatonin also has incredible neuroprotective effects.
  • Studies now reveal that melatonin levels begin to decline at just the time when neurodegenerative diseases begin to rise, and there’s good scientific evidence for a strong connection between these phenomena.
  • Supplemental melatonin restores normal, youthful levels of the hormone, and provides powerful antioxidant protection for the brain.
  • Laboratory and early clinical studies show that melatonin supplementation can protect against the age-induced brain changes leading to Alzheimer’s and Parkinson’s diseases, to increased stroke risk, and to susceptibility to brain trauma.
  • To achieve the most benefit from melatonin, begin supplementation as early as possible.

Melatonin Fights Parkinson’s at the Earliest Stages

Animal studies demonstrate that melatonin supplementation can prevent—and to some extent, even reverse—the changes in behavior and motor function induced by Parkinson’s disease.33-35 Parkinson’s disease robs its victims of normal movement, slowing them down, making their walk erratic, and blocking normal facial expressions.35 All of this occurs through the loss of neurons that produce the neurotransmitter dopamine. 33

Parkinson’s has a number of similarities to Alzheimer’s. Both can lead to dementia. Both are the result of out-of-control oxidation (in the case of Parkinson’s focused on brain regions that control movement and balance).20,35 And in both diseases, brain cell death and dysfunction is brought on by an abnormal, oxidizing, and inflammatory protein accumulation. In Parkinson’s, that protein is called alpha-synuclein. 36,37

Working with various laboratory models of Parkinson’s disease, scientists have demonstrated that melatonin can attack Parkinson’s disease at each of its critical junctures:

  • It prevents the production of alpha-synuclein in brain cells, at the same time attacking existing molecules of the toxic protein and making them available for cellular cleanup.36,37
  • It reverses the inflammatory changes seen in the brains of people with Parkinson’s disease.38
  • It restores normal activity of a key enzyme involved in dopamine production.8,24

Melatonin’s ability to prevent—and reverse—the changes in behavior and motor function induced by the disease is the result of enhanced survival of the dopamine-producing cells that become damaged or destroyed in Parkinson’s disease.8-10

The Hidden Dangers of Sleep Drugs
The Hidden Dangers of Sleep Drugs

Because of the high prevalence of sleep disorders in older adults—even those without dementia—use of benzodiazepine drugs is widespread.64 But these drugs, which include alprazolam (Xanax®), diazepam (Valium®), and Lorazepam (Ativan®), and others, have a nasty but little-known side effect—they suppress melatonin levels.

In studies going back 25 years, benzodiazepines have been proven to suppress melatonin levels.65 In fact, a single dose (2 mg) of alprazolam at 9:00 p.m. was shown to significantly suppress blood melatonin levels at 11:00 p.m., midnight, 1:00 a.m., 6:00 a.m., and 7:00 a.m. 66

That’s troubling because this drug, so often taken for sleep, is in fact depleting the body of its own most potent sleep-inducing hormone. It’s even more troubling because regular benzodiazepine use is now recognized as a risk factor for dementia.64

Research showed that people who used benzodiazepines at any time in their life were at approximately a 50% greater risk for developing dementia than non-users.67 And for those with benzodiazepine dependence, the risk of probable cognitive impairment more than quintupled!68

Given what we know about melatonin’s powerful neuroprotective properties, the conclusion is inescapable that these melatonin-depleting drugs are triggering dementia in people who use them regularly.

If you are using one of these drugs, it would be wise to begin regular melatonin supplementation to restore your levels to the safe range. And if you are using the drugs purely for sleep, consider replacing them (gradually) with melatonin at bedtime.

Melatonin Cuts Stroke Risk

As you age, waning melatonin levels place your brain at risk for both immediate and long-term neurological damage. In particular, decreased melatonin levels have been associated with a greater presence of stroke, with the odds appearing to rise more than 2% for each 1 pg/mL decline in melatonin.39 In people whose pineal gland (the source of melatonin) has become calcified and non-functional, the risk of stroke is increased by 35%.40

Plenty of biochemical evidence is available to explain this increased risk. Much of the damage done in either type of stroke—ischemic (insufficient blood flow) or hemorrhagic (bleeding into the brain)—is the result of free radical production. In an animal model of ischemic stroke, melatonin improved cognition by scavenging and neutralizing free radicals.41

It also reduces indirect risk factors for stroke, such as elevated cholesterol and blood pressure. It has been shown to suppress cholesterol formation by 38%, reduce LDL-cholesterol accumulation by 42%, and reduce blood pressure into the normal range. 42

Melatonin Limits Stroke Damage

Once a stroke has begun to develop, melatonin can prevent the death of neurons in the stroke area—limiting the damage done by the stroke.11 Researchers conducted an experiment in which they removed the pineal glands of rats to make them deficient in melatonin. They found that these rats experienced significantly greater brain damage after a stroke or seizure than the rats that still had sufficient melatonin levels.43

Repeated animal studies have demonstrated that animals supplemented with melatonin prior to a stroke experienced a decrease in the volume of brain tissue affected by an ischemic stroke (the most common kind).11,44-47 This results in improved neurological and behavioral outcomes, and faster recovery from the stroke.11,47,48

One of the most important determinants of a good recovery from a stroke is the degree of “plasticity” in the surviving neurons.49 Plasticity involves how well the surviving neurons are able to shift their function and take on some of the activities of damaged or destroyed brain cells. 49 Melatonin has been found to increase the plasticity of the neurons on both sides of the brain (the affected side and the opposite side)—an effect that hastens recovery.50

Another way melatonin helps reduce the damage caused by a stroke is by reducing the activation of destructive “protein-melting” enzymes.47,51 An ischemic stroke triggers an increase in “protein-melting” enzymes, which impair the integrity of the normal blood-brain barrier, leading to brain swelling, increased pressure, and occasionally transformation into a hemorrhagic (bleeding) stroke.52 However, in experimental models of ischemic stroke, when melatonin is administered during or after ischemia, it reduces the activation of those destructive enzymes, tightens the blood-brain barrier, reduces tissue swelling, and prevents hemorrhagic transformation.11,47,51,53

A Safer Alternative to Prescription Sleep Drugs
A Safer Alternative to Prescription Sleep Drugs

Supplementing with melatonin may reduce the use of prescription sleep medications in the benzodiazepine family (Xanax®, Valium®, and others). In one study, 62.8% of control subjects received such drugs, while only 9.8% of melatonin supplemented patients were prescribed them.31 As a result, in Europe (where melatonin is a drug), a concerted effort is being made to increase awareness and use of melatonin as a way to get people off of these side effect-laden, abuse-prone medications.69


Melatonin Shields Your Brain from Traumatic Injuries

Melatonin has also been found to help protect your brain in the event of a traumatic brain injury (such as head trauma experienced in an automobile accident). Traumatic brain injury is a leading cause of death and disability in younger Americans (but not unheard of in older adults).54,55

Just as in a stroke, oxidative damage to brain cells is the leading culprit in traumatic brain injuries. Also as in a stroke, promoting brain cell plasticity (the ability of surviving neurons to take on some of the activities of damaged brain cells and to promote re-growth of damaged tissue) is a mainstay of treatment.56

Animal studies show that administration of melatonin after such an injury maintains integrity of the blood-brain barrier, prevents dangerous brain swelling in the hours and days following the injury, and shrinks the size of the bruised and injured tissue.55 It has also been found to reduce the mortality rate after a burst aneurysm.12,13

Most of these effects are related to melatonin’s direct antioxidant effects, along with its ability to induce
otherwise dormant cellular antioxidant systems.13

What Is Melatonin?
What Is Melatonin?

Melatonin is a hormone that is primarily secreted in the pineal gland, a minute, pea-sized organ located in the center of the brain between the two hemispheres.16,17,22 Shaped like a tiny pine cone (hence the name), the pineal gland is filled with nerve cells that respond to light or darkness (some biologists refer to the pineal as the “third eye” for this reason).22,70

Through its secretion of melatonin, the pineal gland acts as the body’s central clock, telling the brain and other organs when it’s time to be active and when it’s time to rest.2,16,17,19,22 That’s why melatonin is typically thought of as the “sleep hormone.”17

But in addition to its hormonal actions, melatonin is one of the body’s most powerful intrinsic antioxidants.2,18,28 Melatonin has several antioxidant mechanisms: it directly scavenges free radicals of both oxygen and nitrogen, neutralizes a host of other radicals, and stimulates gene expression of powerful intracellular antioxidant systems.2,3,28 But melatonin has an additional action that sets it apart from other antioxidants: It readily crosses the blood-brain barrier and enters brain cells and their organelles.3

Unfortunately, the pineal gland’s production of melatonin declines rapidly after middle age.2,6,16 Since the brain lacks other oxidative defense mechanisms, the decline in melatonin production leaves brain cells increasingly vulnerable to oxidative damage, resulting in dysfunction at the level of molecules and cells.3

We see the effects of that dysfunction in the various diseases of the aging brain, such as Alzheimer’s, Parkinson’s, Huntington’s, and others.2,3 Oxidative damage also produces the disastrous effects of a stroke or a traumatic brain injury, effects which may be attenuated by melatonin. 2,3,42

Can Melatonin Extend Your Life?

There’s no question that melatonin exerts powerful protective effects on brain tissue. We’ve seen how it can mitigate oxidative damage that contributes to neurodegenerative diseases, stroke, and head trauma.

But melatonin is a potent antioxidant that’s also found in the blood, making it accessible to other tissues throughout the body.57 Could melatonin, then, offer true life extension by preventing damage not just to the brain, but to the entire body?

It’s too early to say definitively, of course. Humans live so long that it’s challenging to conduct an ethical, randomized, placebo-controlled study of most interventions. But studies in other animals yield considerable reason for hope.

In the single-celled organism Paramecium tetraurelia, melatonin treatment increased both the mean and the maximal life span by up to 24% over control animals.58 In fruit flies (Drosophila melanogaster), melatonin-fed flies had a 33% increase in maximum life span and a nearly 14% increase in median life span.59

In higher organisms such as mice and rats, data are promising but incomplete. Melatonin increases expression of the “longevity protein” SIRT1, which triggers the expression of a host of self-healing genes (SIRT1 is activated by calorie restriction).14 One study in mice found no increase in mean life span, but an increase in the life span of the last surviving 10% of the population.60 Another study did show increases in longevity in mice engineered to age rapidly.61

Research also shows that animals undergoing calorie restriction—a documented means of extending life span—substantially increase their production of melatonin.19 And melatonin activates (and synergizes with) some of the same brain-protective mechanisms activated by resveratrol, another life-extending supplement.15,62,63



Melatonin has been ignored or trivialized as simply a “sleep aid” ever since Life Extension introduced it to the world in 1992. But a burst of new studies now reveals that melatonin can protect your brain from many of the ravages of aging.

When we’re young, melatonin protects our brains from free radical attack. But after middle age, melatonin levels drop precipitously, leaving our brains increasingly susceptible to the growing impact of oxidative damage. Such damage leads to increased risk of neurodegenerative diseases and stroke, and increased vulnerability to the effects of head trauma.

Studies now show that melatonin supplementation can normalize oxidative damage in brain tissue. It can protect against the pathological changes seen in Alzheimer’s and Parkinson’s diseases, can shrink the size of the brain area involved in a stroke and can minimize brain swelling and dysfunction following a head injury.

But, like all preventive measures, brain protection with melatonin requires early action. You likely won’t get much benefit from melatonin if you wait until after onset of symptoms of neurodegeneration or until after a stroke or head injury claims some of your brain cells.

In order to keep your brain functioning in top condition, you need to support your dwindling supplies of brain-protective melatonin now.

If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at 1-866-864-3027.


  1. Gutierrez-Cuesta J, Sureda FX, Romeu M, et al. Chronic administration of melatonin reduces cerebral injury biomarkers in SAMP8. J Pineal Res. 2007 Apr;42(4):394-402.
  2. Pandi-Perumal SR, BaHammam AS, Brown GM, et al. Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes. Neurotox Res. 2013 Apr;23(3):267-300.
  3. Gupta YK, Gupta M, Kohli K. Neuroprotective role of melatonin in oxidative stress vulnerable brain. Indian J Physiol Pharmacol. 2003 Oct;47(4):373-86.
  4. Bondy SC, Lahiri DK, Perreau VM, et al. Retardation of brain aging by chronic treatment with melatonin. Ann N Y Acad Sci. 2004 Dec;1035:197-215.
  5. De Rooij SE. Melatonin deficiency hypothesis in delirium. A synthesis of current evidence. Rejuvenation Res. 2013 Apr 19. [Epub ahead of print]
  6. Lahiri DK, Chen DM, Lahiri P, Bondy S, Greig NH. Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases. Ann N Y Acad Sci. 2005 Nov;1056:430-49.
  7. Feng Z, Qin C, Chang Y, Zhang JT. Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer’s disease. Free Radic Biol Med. 2006 Jan 1;40(1):101-9.
  8. Niranjan R, Nath C, Shukla R. The mechanism of action of MPTP-induced neuroinflammation and its modulation by melatonin in rat astrocytoma cells, C6. Free Radic Res. 2010 Nov;44(11):1304-16.
  9. Ma J, Shaw VE, Mitrofanis J. Does melatonin help save dopaminergic cells in MPTP-treated mice? Parkinsonism Relat Disord. 2009 May;15(4):307-14.
  10. Borah A, Mohanakumar KP. Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents. J Pineal Res. 2009 Nov;47(4):293-300.
  11. Reiter RJ, Sainz RM, Lopez-Burillo S, Mayo JC, Manchester LC, Tan DX. Melatonin ameliorates neurologic damage and neurophysiologic deficits in experimental models of stroke. Ann N Y Acad Sci. 2003 May;993:35-47; discussion 48-53.
  12. Ayer RE, Sugawara T, Zhang JH. Effects of melatonin in early brain injury following subarachnoid hemorrhage. Acta Neurochir Suppl. 2008;102:327-30.
  13. Wang Z, Ma C, Meng CJ, et al. Melatonin activates the Nrf2-ARE pathway when it protects against early brain injury in a subarachnoid hemorrhage model. J Pineal Res. 2012 Sep;53(2):129-37.
  14. Chang HM, Wu UI, Lan CT. Melatonin preserves longevity protein (sirtuin 1) expression in the hippocampus of total sleep-deprived rats. J Pineal Res. 2009 Oct;47(3):211-20.
  15. Cristofol R, Porquet D, Corpas R, et al. Neurons from senescence-accelerated SAMP8 mice are protected against frailty by the sirtuin 1 promoting agents melatonin and resveratrol. J Pineal Res. 2012 Apr;52(3):271-81.
  16. Lahiri DK, Chen D, Lahiri P, Rogers JT, Greig NH, Bondy S. Melatonin, metals, and gene expression: implications in aging and neurodegenerative disorders. Ann N Y Acad Sci. 2004 Dec;1035:216-30.
  17. Fernandez-Tresguerres Hernandez JA. Melatonina: old molecule, new medicament. An R Acad Nac Med (Madr). 2008;125(4):681-96.
  18. Feng Z, Zhang JT. Long-term melatonin or 17-beta-estradiol supplementation alleviates oxidative stress in ovariectomized adult rats. Free Radic Biol Med. 2005 Jul 15;39(2):195-204.
  19. Bubenik GA, Konturek SJ. Melatonin and aging: prospects for human treatment. J Physiol Pharmacol. 2011 Feb;62(1):13-9.
  20. Wang JZ, Wang ZF. Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol Sin. 2006 Jan;27(1):41-9.
  21. Liu RY, Zhou JN, van Heerikhuize J, Hofman MA, Swaab DF. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer’s disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab. 1999 Jan;84(1):323-7.
  22. Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer’s disease. J Pineal Res. 2005 Apr;38(3):145-52.
  23. Cardinali DP, Furio AM, Brusco LI. Clinical aspects of melatonin intervention in Alzheimer’s disease progression. Curr Neuropharmacol. 2010 Sep;8(3):218-27.
  24. Cardinali DP, Brusco LI, Liberczuk C, Furio AM. The use of melatonin in Alzheimer’s disease. Neuro Endocrinol Lett. 2002 Apr;23 Suppl 1:20-3.
  25. Cardinali DP, Furio AM, Brusco LI. The use of chronobiotics in the resynchronization of the sleep/wake cycle. Therapeutical application in the early phases of Alzheimer’s disease. Recent Pat Endocr Metab Immune Drug Discov. 2011 May;5(2):80-90.
  26. Zhu LQ, Wang SH, Ling ZQ, Wang DL, Wang JZ. Effect of inhibiting melatonin biosynthesis on spatial memory retention and tau phosphorylation in rat. J Pineal Res. 2004 Sep;37(2):71-7.
  27. Wang S, Zhu L, Shi H, et al. Inhibition of melatonin biosynthesis induces neurofilament hyperphosphorylation with activation of cyclin-dependent kinase 5. Neurochem Res. 2007 Aug;32(8):1329-35.
  28. Daniels WM, van Rensburg SJ, van Zyl JM, Taljaard JJ. Melatonin prevents beta-amyloid-induced lipid peroxidation. J Pineal Res. 1998 Mar;24(2):78-82.
  29. Lahiri DK, Chen D, Ge YW, Bondy SC, Sharman EH. Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex. J Pineal Res. 2004 May;36(4):224-31.
  30. Feng Z, Chang Y, Cheng Y, et al. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer’s disease. J Pineal Res. 2004 Sep;37(2):129-36.
  31. Cardinali DP, Vigo DE, Olivar N, Vidal MF, Furio AM, Brusco LI. Therapeutic application of melatonin in mild cognitive impairment. Am J Neurodegener Dis. 2012;1(3):280-91.
  32. Furio AM, Brusco LI, Cardinali DP. Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study. J Pineal Res. 2007 Nov;43(4):404-9.
  33. Capitelli C, Sereniki A, Lima MM, Reksidler AB, Tufik S, Vital MA. Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats. Eur J Pharmacol. 2008 Oct 10;594(1-3):101-8.
  34. Gutierrez-Valdez AL, Anaya-Martinez V, Ordonez-Librado JL, et al. Effect of chronic L-dopa or melatonin treatments after dopamine deafferentation in rats: dyskinesia, motor performance, and cytological analysis. ISRN Neurol. 2012;2012:360379.
  35. Patki G, Lau YS. Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson’s disease. Pharmacol Biochem Behav. 2011 Oct;99(4):704-11.
  36. Ono K, Mochizuki H, Ikeda T, et al. Effect of melatonin on alpha-synuclein self-assembly and cytotoxicity. Neurobiol Aging. 2012 Sep;33(9):2172-85.
  37. Sae-Ung K, Ueda K, Govitrapong P, Phansuwan-Pujito P. Melatonin reduces the expression of alpha-synuclein in the dopamine containing neuronal regions of amphetamine-treated postnatal rats. J Pineal Res. 2012 Jan;52(1):128-37.
  38. Brito-Armas JM, Baekelandt V, Castro-Hernandez JR, Gonzalez-Hernandez T, Rodriguez M, Castro R. Melatonin prevents dopaminergic cell loss induced by lentiviral vectors expressing A30P mutant alpha-synuclein. Histol Histopathol. 2013 Feb 27.
  39. Atanassova PA, Terzieva DD, Dimitrov BD. Impaired nocturnal melatonin in acute phase of ischaemic stroke: cross-sectional matched case-control analysis. J Neuroendocrinol. 2009 Jul;21(7):657-63.
  40. Kitkhuandee A, Sawanyawisuth K, Johns NP, Kanpittaya J, Johns J. Pineal Calcification is Associated with Symptomatic Cerebral Infarction. J Stroke Cerebrovasc Dis. 2013 Feb 20.
  41. Deykun K, Pometlova M, Schutova B, Mares J. Modulations of behavioral consequences of minor cortical ischemic lesion by application of free radicals scavengers. Gen Physiol Biophys. 2011 Sep;30(3):263-70.
  42. Sewerynek E. Melatonin and the cardiovascular system. Neuro Endocrinol Lett. 2002 Apr;23 Suppl 1:79-83.
  43. Manev H, Uz T, Kharlamov A, Joo JY. Increased brain damage after stroke or excitotoxic seizures in melatonin-deficient rats. FASEB J. 1996 Nov;10(13):1546-51.
  44. Shinozuka K, Staples M, Borlongan CV. Melatonin-based therapeutics for neuroprotection in stroke. Int J Mol Sci. 2013 Apr 25;14(5):8924-47.
  45. Pei Z, Ho HT, Cheung RT. Pre-treatment with melatonin reduces volume of cerebral infarction in a permanent middle cerebral artery occlusion stroke model in the rat. Neurosci Lett. 2002 Feb 1;318(3):141-4.
  46. Pei Z, Pang SF, Cheung RT. Pretreatment with melatonin reduces volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. J Pineal Res. 2002 Apr;32(3):168-72.
  47. Hung YC, Chen TY, Lee EJ, et al. Melatonin decreases matrix metalloproteinase-9 activation and expression and attenuates reperfusion-induced hemorrhage following transient focal cerebral ischemia in rats. J Pineal Res. 2008 Nov;45(4):459-67.
  48. de Courten Myers GM, Kleinholz M, Wagner KR, Myers RE. Stroke assessment: morphometric infarct size versus neurologic deficit. J Neurosci Methods. 1998 Sep 1;83(2):151-7.
  49. Dietrichs E. Brain plasticity after stroke--implications for post-stroke rehabilitation. Tidsskr Nor Laegeforen. 2007 May 3;127(9):1228-31.
  50. Chen HY, Hung YC, Chen TY, et al. Melatonin improves presynaptic protein, SNAP-25, expression and dendritic spine density and enhances functional and electrophysiological recovery following transient focal cerebral ischemia in rats. J Pineal Res. 2009 Oct;47(3):260-70.
  51. Jang JW, Lee JK, Lee MC, Piao MS, Kim SH, Kim HS. Melatonin reduced the elevated matrix metalloproteinase-9 level in a rat photothrombotic stroke model. J Neurol Sci. 2012 Dec 15;323(1-2):221-7.
  52. Dong X, Song YN, Liu WG, Guo XL. Mmp-9, a potential target for cerebral ischemic treatment. Curr Neuropharmacol. 2009 Dec;7(4):269-75.
  53. Reiter RJ, Tan DX, Leon J, Kilic U, Kilic E. When melatonin gets on your nerves: its beneficial actions in experimental models of stroke. Exp Biol Med (Maywood). 2005 Feb;230(2):104-17.
  54. Tsai MC, Chen WJ, Tsai MS, Ching CH, Chuang JI. Melatonin attenuates brain contusion-induced oxidative insult, inactivation of signal transducers and activators of transcription 1, and upregulation of suppressor of cytokine signaling-3 in rats. J Pineal Res. 2011 Sep;51(2):233-45.
  55. Ismailoglu O, Atilla P, Palaoglu S, et al. The therapeutic effects of melatonin and nimodipine in rats after cerebral cortical injury. Turk Neurosurg. 2012;22(6):740-6.
  56. Flanagan SR, Cantor JB, Ashman TA. Traumatic brain injury: future assessment tools and treatment prospects. Neuropsychiatr Dis Treat. 2008 Oct;4(5):877-92.
  57. Sae-Teaw M, Johns J, Johns NP, Subongkot S. Serum melatonin levels and antioxidant capacities after consumption of pineapple, orange, or banana by healthy male volunteers. J Pineal Res. 2012 Oct 5.
  58. Thomas JN, Smith-Sonneborn J. Supplemental melatonin increases clonal lifespan in the protozoan Paramecium tetraurelia. J Pineal Res. 1997 Oct;23(3):123-30.
  59. Bonilla E, Medina-Leendertz S, Diaz S. Extension of life span and stress resistance of Drosophila melanogaster by long-term supplementation with melatonin. Exp Gerontol. 2002 May;37(5):629-38.
  60. Anisimov VN, Alimova IN, Baturin DA, et al. Dose-dependent effect of melatonin on life span and spontaneous tumor incidence in female SHR mice. Exp Gerontol. 2003 Apr;38(4):449-61.
  61. Rodriguez MI, Escames G, Lopez LC, et al. Improved mitochondrial function and increased life span after chronic melatonin treatment in senescent prone mice. Exp Gerontol. 2008 Aug;43(8):749-56.
  62. Kwon KJ, Kim JN, Kim MK, et al. Melatonin synergistically increases resveratrol-induced heme oxygenase-1 expression through the inhibition of ubiquitin-dependent proteasome pathway: a possible role in neuroprotection. J Pineal Res. 2011 Mar;50(2):110-23.
  63. Kwon KJ, Kim HJ, Shin CY, Han SH. Melatonin Potentiates the Neuroprotective Properties of Resveratrol Against Beta-Amyloid-Induced Neurodegeneration by Modulating AMP-Activated Protein Kinase Pathways. J Clin Neurol. 2010 Sep;6(3):127-37.
  64. Gallacher J, Elwood P, Pickering J, Bayer A, Fish M, Ben-Shlomo Y. Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Community Health. 2012 Oct;66(10):869-73.
  65. McIntyre IM, Burrows GD, Norman TR. Suppression of plasma melatonin by a single dose of the benzodiazepine alprazolam in humans. Biol Psychiatry. 1988 May;24(1):108-12.
  66. McIntyre IM, Norman TR, Burrows GD, Armstrong SM. Alterations to plasma melatonin and cortisol after evening alprazolam administration in humans. Chronobiol Int. 1993 Jun;10(3):205-13.
  67. Billioti de Gage S, Begaud B, Bazin F, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 2012;345:e6231.
  68. Potvin O, Hudon C, Forget H, et al. Prevalence of psychiatric disorders in community-dwelling older men and women with cognitive impairment no dementia: results from the ESA study. Aging Ment Health. 2012;16(2):218-27.
  69. Clay E, Falissard B, Moore N, Toumi M. Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and z-drugs consumption in nine European countries. Eur J Clin Pharmacol. 2013 Apr;69(4):1-10.
  70. Mano H, Fukada Y. A median third eye: pineal gland retraces evolution of vertebrate photoreceptive organs. Photochem Photobiol. 2007 Jan-Feb;83(1):11-8.